Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bretten – page 55

1 040 clinical trials in Bretten, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bretten at a glance
1 040
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 040 trials in Bretten

Open in trial search

Study of BI-1607, Ipilimumab, and Pembrolizumab for Patients with Advanced Melanoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI-1607
  • Sponsor:BioInvent International AB

Study of Quizartinib with Chemotherapy for Adults with Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Daiichi Sankyo Inc.

Pulmonary fibrosis

Not recruiting

Study on the Effects of Inhaled Treprostinil for Patients with Progressive Pulmonary Fibrosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil
  • Sponsor:United Therapeutics Corp.

Study on the Effectiveness and Safety of ANX007 Injections for Patients with Geographic Atrophy from Age-Related Macular Degeneration

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ANX007
  • Sponsor:Annexon Inc.

Study of Eftilagimod Alfa with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Immutep

Study of Axicabtagene Ciloleucel for Patients with Relapsed or Refractory Primary Mediastinal B-Cell Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Axicabtagene Ciloleucel
  • Sponsor:Universitaet Muenster

Breast cancer+4

Not recruiting

Study of Pembrolizumab and Olaparib for Patients with Advanced HER2 Negative Breast Cancer and Specific Genetic Mutations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:Institut Für Frauengesundheit GmbH

Study of RMC-6236 compared to standard therapy in previously treated metastatic pancreatic ductal adenocarcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Daraxonrasib
  • Sponsor:Revolution Medicines Inc.

Study on the Effects of Mosliciguat for Patients with Pulmonary Hypertension Linked to Interstitial Lung Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Mosliciguat
  • Sponsor:Pulmovant Inc.

Pancreatic carcinoma

Not recruiting

Study on Quemliclustat and Chemotherapy for Patients with Metastatic Pancreatic Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Arcus Biosciences Inc.

Study of Sotatercept for People with Pulmonary Arterial Hypertension

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept
  • Sponsor:Merck Sharp & Dohme LLC

Colitis ulcerative

Not recruiting

Study on the Effects of Zasocitinib for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bretten

What the registry says about research in the country

01 Infectious Disease Prevention

Ongoing clinical trials focusing on meningococcal infection prevention through vaccination studies. Research is evaluating the long-term effectiveness of a quadrivalent conjugate vaccine in providing protection against multiple bacterial strains.

  • Vaccine Immunogenicity
  • Long-term Protection
  • Pediatric Vaccination

Studies involve children and adolescents across multiple European centers, examining immune responses and safety profiles of booster vaccinations administered at 5- and 10-year intervals.

02 Pediatric Immunology

Research centered on understanding the persistence of immunity in young populations. The booster vaccination studies are specifically designed to evaluate immune system responses in previously vaccinated children.

  • Immune Response Duration
  • Booster Effectiveness
  • Safety Assessment

These trials are being conducted across multiple sites in Finland, Germany, Spain, and Hungary, focusing on protective immunity development in pediatric populations.

03 Preventive Medicine

Investigation of preventive strategies against multiple meningococcal serogroups through advanced vaccine technology. The research aims to establish optimal timing for booster doses.

  • Multi-strain Protection
  • Vaccination Schedule Optimization
  • Population Health Impact

The study evaluates the effectiveness of vaccination strategies in providing comprehensive protection against various meningococcal strains.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.